Efficacy of concurrent chemoradiotherapy with retrograde super selective intra-arterial infusion combined with cetuximab for synchronous multifocal oral squamous cell carcinomas.
Male
Humans
Aged
Carcinoma, Squamous Cell
/ therapy
Squamous Cell Carcinoma of Head and Neck
/ therapy
Mouth Neoplasms
/ therapy
Cetuximab
Tongue Neoplasms
/ drug therapy
Infusions, Intra-Arterial
/ methods
Docetaxel
Taxoids
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Cisplatin
Chemoradiotherapy
/ methods
Head and Neck Neoplasms
Cetuximab
Intra-arterial chemotherapy
Oral squamous cell carcinoma
Synchronous multifocal cancer
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
26 May 2023
26 May 2023
Historique:
received:
05
07
2022
accepted:
16
05
2023
medline:
29
5
2023
pubmed:
27
5
2023
entrez:
26
5
2023
Statut:
epublish
Résumé
The incidence of multicentric oral cancer is increasing. However, treatment encounters difficulty if each tumor needs to be treated simultaneously. The objective of this clinical case report is to highlight the effect of concurrent chemoradiotherapy with retrograde superselective intra-arterial infusion combined with systemic administration of cetuximab on synchronous multifocal oral squamous cell carcinomas. A 70-year-old man presented to the hospital with multiple tumors and oral pain. Three independent tumors were found in the right dorsal tongue, left edge of the tongue, and left lower lip. Based on the characteristic appearance of the lesions and further evaluation, clinical diagnoses of right tongue cancer "T3", left tongue cancer "T2" and lower left lip cancer "T1", N2cM0 were made. Treatment was initiated with systemic administration of cetuximab, followed by intra-arterial chemoradiotherapy. Treatment results were complete response on all three local lesions, and left neck dissection was performed following the initial treatment. The patient showed no evidence of recurrence during the 4 years follow-up period. This novel combination treatment seems to be a promising strategy for patients with synchronous multifocal oral squamous cell carcinoma.
Sections du résumé
BACKGROUND
BACKGROUND
The incidence of multicentric oral cancer is increasing. However, treatment encounters difficulty if each tumor needs to be treated simultaneously. The objective of this clinical case report is to highlight the effect of concurrent chemoradiotherapy with retrograde superselective intra-arterial infusion combined with systemic administration of cetuximab on synchronous multifocal oral squamous cell carcinomas.
CASE PRESENTATION
METHODS
A 70-year-old man presented to the hospital with multiple tumors and oral pain. Three independent tumors were found in the right dorsal tongue, left edge of the tongue, and left lower lip. Based on the characteristic appearance of the lesions and further evaluation, clinical diagnoses of right tongue cancer "T3", left tongue cancer "T2" and lower left lip cancer "T1", N2cM0 were made. Treatment was initiated with systemic administration of cetuximab, followed by intra-arterial chemoradiotherapy. Treatment results were complete response on all three local lesions, and left neck dissection was performed following the initial treatment. The patient showed no evidence of recurrence during the 4 years follow-up period.
CONCLUSIONS
CONCLUSIONS
This novel combination treatment seems to be a promising strategy for patients with synchronous multifocal oral squamous cell carcinoma.
Identifiants
pubmed: 37237293
doi: 10.1186/s13014-023-02282-9
pii: 10.1186/s13014-023-02282-9
pmc: PMC10224585
doi:
Substances chimiques
Cetuximab
PQX0D8J21J
Docetaxel
15H5577CQD
Taxoids
0
Cisplatin
Q20Q21Q62J
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
90Subventions
Organisme : Japan Society for the Promotion of Science
ID : JSPS KAKENHI, Grant Number 18K09820
Informations de copyright
© 2023. The Author(s).
Références
Oral Oncol. 2018 Apr;79:71-77
pubmed: 29598953
Int J Oral Maxillofac Surg. 2002 Aug;31(4):427-33
pubmed: 12361079
Radiother Oncol. 2014 May;111(2):306-10
pubmed: 24746571
Mol Clin Oncol. 2016 Aug;5(2):246-252
pubmed: 27446558
AJNR Am J Neuroradiol. 2010 Apr;31(4):626-7
pubmed: 20167650
N C Dent J. 1973 Aug;56(3):21-3
pubmed: 4516381
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Oral Oncol. 1999 Mar;35(2):157-63
pubmed: 10435150
Tokai J Exp Clin Med. 2000 Dec;25(4-6):165-71
pubmed: 11358031
Cancer. 1961 Mar-Apr;14:221-30
pubmed: 13771652
Oral Oncol. 1998 Sep;34(5):387-90
pubmed: 9861346
Radiother Oncol. 2014 Jan;110(1):172-81
pubmed: 24183870
Clin Transl Immunology. 2015 Jul 17;4(7):e39
pubmed: 26246897
Cancer. 1994 Oct 1;74(7):1933-8
pubmed: 8082099
Lancet Oncol. 2010 Jan;11(1):21-8
pubmed: 19897418